MBX Steven L Hoerter buys $265K worth of shares
Oct 21, 2025, 10:39 AM
0.00%
What does MBX do
MBX Biosciences, a clinical-stage biopharmaceutical company based in Carmel, Indiana, focuses on precision peptide therapies for endocrine and metabolic disorders and went public on September 13, 2024. Its product candidates include MBX 2109, MBX 1416, and MBX 4291, targeting various hormone-related conditions.
Steven L Hoerter bought 20,000 shares of MBX on 17 October at $13.25 per share, worth a total of $265K. They now own 20,000 MBX shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.